Integra LifeSciences (NASDAQ:IART) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

According to Zacks, “Integra LifeSciences exited the third quarter of 2017 on a disappointing note with earnings and revenues both missing the respective Zacks Consensus Estimate. Also, contraction in adjusted operating margin and adjusted gross margin adds to the woes. Also the company’s decision to sell its certain neurosurgery assets to Natus Medical may hamper its business in near term. However, the strong year-over-year increase in revenues on the back of strong growth within Orthopedics and Tissue Technologies segment buoys optimism. Raised full-year revenue guidance is indicative of this bullish trend to remain. We are happy with the fact that, the company is efficiently executing its growth plan through an efficient management team. However, the slashed full-year adjusted earnings range remains a concern. Overall, over the last six months, Integra Lifesciences has been trading slightly above the broader industry.”

A number of other research analysts have also recently weighed in on IART. Oppenheimer set a $58.00 target price on Integra LifeSciences and gave the company a “buy” rating in a report on Tuesday. Royal Bank of Canada restated a “sector perform” rating and set a $50.00 price objective (up previously from $48.00) on shares of Integra LifeSciences in a research note on Thursday, November 9th. UBS reiterated a “buy” rating and issued a $57.00 price target on shares of Integra LifeSciences in a research note on Tuesday, October 31st. Wells Fargo & Company cut Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research note on Sunday, October 29th. Finally, Jefferies Group reissued a “buy” rating and issued a $56.00 price objective on shares of Integra LifeSciences in a report on Sunday, October 29th. One analyst has rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $53.64.

Integra LifeSciences (IART) traded up $0.19 during midday trading on Wednesday, reaching $49.02. The company had a trading volume of 636,800 shares, compared to its average volume of 593,786. Integra LifeSciences has a 12-month low of $40.51 and a 12-month high of $56.42. The stock has a market cap of $3,832.05, a P/E ratio of 26.98, a P/E/G ratio of 2.14 and a beta of 0.65. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.47 by ($0.02). Integra LifeSciences had a net margin of 4.52% and a return on equity of 16.35%. The firm had revenue of $278.83 million during the quarter, compared to analysts’ expectations of $286.00 million. During the same period in the previous year, the business earned $0.93 earnings per share. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. equities research analysts anticipate that Integra LifeSciences will post 1.85 earnings per share for the current year.

In related news, Director Barbara B. Hill acquired 10,768 shares of the business’s stock in a transaction dated Tuesday, October 31st. The stock was bought at an average price of $46.66 per share, for a total transaction of $502,434.88. Following the transaction, the director now owns 55,540 shares of the company’s stock, valued at $2,591,496.40. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Richard D. Gorelick sold 1,500 shares of the stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total value of $70,785.00. Following the sale, the vice president now owns 21,665 shares of the company’s stock, valued at approximately $1,022,371.35. The disclosure for this sale can be found here. Corporate insiders own 21.50% of the company’s stock.

Large investors have recently made changes to their positions in the business. Acrospire Investment Management LLC raised its stake in Integra LifeSciences by 280.0% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after purchasing an additional 1,400 shares during the period. Riverhead Capital Management LLC raised its stake in Integra LifeSciences by 49.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after purchasing an additional 799 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Integra LifeSciences by 8.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock worth $150,000 after acquiring an additional 218 shares during the last quarter. Whittier Trust Co. acquired a new position in shares of Integra LifeSciences in the third quarter worth $169,000. Finally, San Francisco Sentry Investment Group CA acquired a new position in shares of Integra LifeSciences in the second quarter worth $174,000. 87.62% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Get a free copy of the Zacks research report on Integra LifeSciences (IART)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with's FREE daily email newsletter.